Debjit Chattopadhyay's Stock Ratings

Guggenheim Analyst

Debjit Chattopadhyay is an analyst at Guggenheim. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/07/2024

Overall Average Return

2.70%

Smart Score

57.9%

Overall Average Return Percentile

44th

Number of Ratings

34
Buy NowGet Alert
06/28/2024CRSPBuy Now
CRISPR Therapeutics
$53.65Assumes → NeutralGet Alert
05/14/2024FOLDBuy Now
Amicus Therapeutics
$10.1727.83% → $13UpgradeNeutral → BuyGet Alert
04/30/2024DTILBuy Now
Precision BioSciences
$9.40102.13% → $19Initiates → BuyGet Alert
04/18/2024VRTXBuy Now
Vertex Pharmaceuticals
$481.89-6.62%$445 → $450MaintainsBuyGet Alert
03/26/2024VYGRBuy Now
Voyager Therapeutics
$7.41196.9% → $22Initiates → BuyGet Alert
03/07/2024DYNBuy Now
Dyne Therapeutics
$33.6110.09%$33 → $37MaintainsBuyGet Alert
03/05/2024PRMEBuy Now
Prime Medicine
$5.52262.32%$24 → $20MaintainsBuyGet Alert
02/27/2024KRYSBuy Now
Krystal Biotech
$191.29-8.52%$130 → $175MaintainsBuyGet Alert
01/18/2024NAMSBuy Now
NewAmsterdam Pharma
$20.0050% → $30Initiates → BuyGet Alert
11/21/2023SLNOBuy Now
Soleno Therapeutics
$42.41-5.68% → $40Assumes → BuyGet Alert
09/13/2023BMRNBuy Now
Biomarin Pharmaceutical
$82.6833.04% → $110ReiteratesBuy → BuyGet Alert
08/15/2023CNTABuy Now
Centessa Pharmaceuticals
$9.0210.86%$9 → $10MaintainsBuyGet Alert
07/31/2023PRMEBuy Now
Prime Medicine
$5.52334.78% → $24Initiates → BuyGet Alert
06/12/2023CNTABuy Now
Centessa Pharmaceuticals
$9.02-0.22% → $9Initiates → BuyGet Alert
05/22/2023KRYSBuy Now
Krystal Biotech
$191.29-32.04%$101 → $130MaintainsBuyGet Alert
05/02/2023VRTXBuy Now
Vertex Pharmaceuticals
$481.89-20.11%$339 → $385MaintainsBuyGet Alert
04/27/2023BMRNBuy Now
Biomarin Pharmaceutical
$82.6845.14%$125 → $120MaintainsBuyGet Alert
02/28/2023QUREBuy Now
uniQure
$3.781302.12% → $53Reiterates → BuyGet Alert
02/28/2023KRYSBuy Now
Krystal Biotech
$191.29-47.2% → $101Reiterates → BuyGet Alert
02/28/2023BMRNBuy Now
Biomarin Pharmaceutical
$82.6851.19% → $125Reiterates → BuyGet Alert
01/26/2023DYNBuy Now
Dyne Therapeutics
$33.61-1.81% → $33Initiates → BuyGet Alert
11/21/2022ALLOBuy Now
Allogene Therapeutics
$2.241194.64%$43 → $29MaintainsBuyGet Alert
11/11/2022PASGBuy Now
Passage Bio
$0.931078.74%$13 → $11MaintainsBuyGet Alert
10/13/2022RAREBuy Now
Ultragenyx Pharmaceutical
$41.4920.51% → $50UpgradeNeutral → BuyGet Alert
06/27/2022ALNYBuy Now
Alnylam Pharmaceuticals
$255.11DowngradeBuy → NeutralGet Alert
03/01/2022IONSBuy Now
Ionis Pharmaceuticals
$47.2435.48% → $64Initiates → BuyGet Alert
01/31/2022SRRABuy Now
Sierra Oncology
$35 → $51MaintainsBuyGet Alert
01/05/2022BEAMBuy Now
Beam Therapeutics
$23.32457.46% → $130Initiates → BuyGet Alert
12/16/2021TSHABuy Now
Taysha Gene Therapies
$2.221161.26%Initiates → BuyGet Alert
12/01/2021VRTXBuy Now
Vertex Pharmaceuticals
$481.89-40.65%$250 → $286MaintainsBuyGet Alert
06/01/2021TALSBuy Now
Talaris Therapeutics
→ $260Initiates → BuyGet Alert
03/31/2020AVROBuy Now
Avrobio
$420 → $156DowngradeBuy → NeutralGet Alert
03/11/2020DTILBuy Now
Precision BioSciences
$9.40102.13%$630 → $570MaintainsBuyGet Alert
09/17/2018AVROBuy Now
Avrobio
→ $564Initiates → BuyGet Alert

Recent Analyst Stock Rating News

The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free